W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > November 2008

NIDA/NIH Request for Applications: Secondary Data Analyses for Substance Abuse Research (R21/R33)

From: Skinner, Karen (NIH/NIDA) [E] <kskinner@nida.nih.gov>
Date: Thu, 6 Nov 2008 11:19:46 -0500
Message-ID: <657022BABDC168438DC5B0AD36A803A50508247B@NIHCESMLBX8.nih.gov>
To: <public-semweb-lifesci@w3.org>
 Secondary Data Analyses for Substance Abuse Research (R21/R33) 

 Application Due Date(s):  January 28, 2009 


*	Purpose.  This funding opportunity, issued by the National
Institute on Drug Abuse invites Phased Innovation (R21/R33) grant
applications from organizations/institutions that propose to conduct
secondary analyses of rich biological data sets related to substance
abuse research and to advance data and computational infrastructure
relevant to the proposed analyses.   
*	Mechanism of Support. This FOA will utilize the
Exploratory/Developmental Phased Innovation (R21/R33) grant mechanism.
Applicants will submit a single application organized into two phases,
beginning with discussion of the R21 phase followed by discussion of the
R33 phase. Applicants using only the R21 mechanism or only the R33
mechanism will not be considered.  
*	Funds Available and Anticipated Number of Awards. NIDA intends
to commit approximately $2,000,000 in FY 2009 to fund 7 to 10 grants.
Funding will be based on scientific and technical merit, program
priorities, and availability of funds. Because the nature and scope of
the proposed research will vary from application to application, it is
anticipated that the size and duration of each award also will vary. 
*	 Budget and Project Period. The total project period for an
application submitted in response to this funding opportunity may not
exceed 4 years.  Awards will support milestone driven
exploratory/feasibility "proof of concept" studies (R21 phase, up to two
years), with possible rapid transition to expedited development (R33
phase, up to three years, depending upon the requested period for the
R21 phase).  Direct costs are limited to $260,000 over a R21 two-year
period, with a maximum of $200,000 allowed in any single year.  The R33
award phase will be limited to $240,000 in direct costs per year.  NIDA
anticipates that a maximum of 50%-70% of the funded R21 phase awards
will progress to the R33 award. 

Scientific/Research Contact 

Karen Skinner, Ph.D. 
Division of Basic Neuroscience and Behavioral Research 
National Institute on Drug Abuse 
6001 Executive Boulevard, Room 4243, MSC 9555
Bethesda, MD 20892-9555
Telephone: (301) 435-0886 
Email: kskinner@mail.nih.gov 
Received on Thursday, 6 November 2008 16:22:42 UTC

This archive was generated by hypermail 2.4.0 : Friday, 17 January 2020 17:20:39 UTC